Last updated: February 19, 2026
This analysis details the patent CL2013003630 granted in Chile, focusing on its claims, protected subject matter, and its position within the relevant pharmaceutical patent landscape. The patent, titled "METHOD FOR TREATING AND PREVENTING HEPATITIS B INFECTION," was filed by Gilead Sciences, Inc.
What is the Protected Subject Matter of CL2013003630?
Patent CL2013003630 protects a method for treating and preventing Hepatitis B infection. The core of the patent lies in the use of specific antiviral compounds, primarily tenofovir disoproxil fumarate (TDF), in a therapeutic regimen.
The patent's claims define the specific uses and compositions involving TDF. These include:
- Claim 1: A method for treating a Hepatitis B virus (HBV) infection in a subject. This method comprises administering to the subject an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. Formula I generally refers to TDF, a prodrug of tenofovir.
- Claim 2: The method of claim 1, wherein the compound is tenofovir disoproxil fumarate. This explicitly names the fumarate salt form of TDF.
- Claim 3: The method of claim 1, further comprising administering a second antiviral agent. This indicates combination therapy is also covered.
- Claim 4: The method of claim 3, wherein the second antiviral agent is selected from the group consisting of lamivudine, adefovir dipivoxil, entecavir, and telbivudine. This specifies certain nucleoside or nucleotide analog reverse transcriptase inhibitors commonly used in HBV treatment.
- Claim 5: The method of claim 1, wherein the subject is a human. This clarifies the target patient population.
- Claim 6: The method of claim 1, wherein the HBV infection is chronic. This narrows the scope to chronic Hepatitis B, a prevalent form of the disease.
- Claim 7: A pharmaceutical composition for treating a Hepatitis B virus (HBV) infection in a subject. This composition comprises a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. This covers the formulation aspect.
- Claim 8: The pharmaceutical composition of claim 7, wherein the compound is tenofovir disoproxil fumarate.
- Claim 9: The pharmaceutical composition of claim 7, further comprising a second antiviral agent.
- Claim 10: The pharmaceutical composition of claim 9, wherein the second antiviral agent is selected from lamivudine, adefovir dipivoxil, entecavir, and telbivudine.
- Claim 11: The pharmaceutical composition of claim 7, wherein the subject is a human.
- Claim 12: The pharmaceutical composition of claim 7, wherein the HBV infection is chronic.
The patent also defines "effective amount" and provides details on administration routes and dosages, though these are more descriptive than core claim limitations. The primary protection is for the use of TDF, alone or in combination, for treating or preventing Hepatitis B infection in humans, particularly chronic HBV.
What are the Key Inclusions and Exclusions from the Patent's Scope?
The scope of CL2013003630 is defined by the specific claims.
Key Inclusions:
- Compound: Tenofovir disoproxil fumarate (TDF) or its pharmaceutically acceptable salts.
- Indication: Treatment and prevention of Hepatitis B virus (HBV) infection.
- Patient Population: Human subjects.
- Disease State: Specifically covers chronic HBV infections.
- Therapeutic Modality: Includes monotherapy with TDF and combination therapy with specified second antiviral agents.
- Formulation: Pharmaceutical compositions containing TDF and a carrier.
Potential Exclusions (based on typical patent limitations and common knowledge of the field):
- Different Salts or Forms of Tenofovir: While the patent mentions "a pharmaceutically acceptable salt thereof," it may not broadly cover all possible salts or polymorphic forms if they are not explicitly claimed or are known in the prior art and not specifically included. However, TDF itself is the direct target.
- Other Antiviral Agents: The patent specifically lists second antiviral agents for combination therapy. Compounds not on this list would not be directly covered by those specific combination claims.
- Treatment of Other Viral Infections: The patent is narrowly focused on HBV. It does not claim methods for treating other viral diseases, such as Hepatitis C or HIV.
- Methods of Manufacture: While a patent may indirectly protect manufacturing processes, the claims of CL2013003630 are directed to the method of use and pharmaceutical compositions, not the synthesis of TDF itself.
- Non-Human Applications: The claims are limited to human subjects.
The patent's strength lies in its protection of the specific therapeutic application of TDF for Hepatitis B.
What is the Patent Landscape for Hepatitis B Treatments in Chile?
The patent landscape for Hepatitis B treatments in Chile, particularly concerning nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs/NtRTIs), is competitive and characterized by the presence of innovator patents, authorized generics, and potentially other independent patents covering different aspects of treatment or compounds.
Innovator Patents: Gilead Sciences, as the holder of CL2013003630, is a major player in the Hepatitis B treatment market. TDF (marketed as Viread) was a cornerstone therapy. The patent landscape reflects the protection sought for such key compounds.
Generic Entry and Authorized Generics: Once innovator patents for compounds like TDF begin to expire or are successfully challenged, generic manufacturers can enter the market. Chile, like many countries, has mechanisms for the approval of generic drugs. Authorized generics, manufactured by the innovator company or under license, are also common, often introduced around the time of patent expiry to preempt independent generic competition.
Other NRTIs/NtRTIs: Patents covering other NRTIs/NtRTIs used for Hepatitis B, such as entecavir (Baraclude, also by Gilead), lamivudine (Heptodin, Epivir), and adefovir dipivoxil (Hepsera), would also form part of the landscape. Each of these compounds has its own patent history and protection periods in Chile.
Combination Therapies: As CL2013003630 itself claims combination therapies, other patents may exist for specific fixed-dose combinations of antiviral agents, or for novel synergistic combinations that offer improved efficacy or safety profiles.
Second Medical Use Patents: While CL2013003630 is a method of use patent, the patent landscape may also include "second medical use" patents. These protect a new use of an already known compound. For example, if a compound was initially developed for HIV but later found to be effective for Hepatitis B, a second medical use patent could be obtained for that specific HBV indication.
Biosimilar/Generic Challenges: The patent landscape is dynamic. Competitors may seek to invalidate existing patents through legal challenges or explore the possibility of developing biosimilars or generics, especially if manufacturing processes or specific formulations are patented.
Data Protection and Market Exclusivity: Beyond patent protection, regulatory data protection periods can provide an additional layer of market exclusivity for a period after a drug's initial marketing authorization, regardless of patent status.
For CL2013003630, its relevance in the current landscape depends on its expiry date and whether any subsequent patents or regulatory exclusivities apply to TDF or its use in Chile. Patents for the compound itself, its formulation, and specific therapeutic uses are crucial considerations. Companies looking to enter the Chilean market with TDF-based Hepatitis B treatments would need to conduct thorough freedom-to-operate (FTO) analyses to navigate this complex landscape.
What are the Implications of CL2013003630 for R&D and Investment?
Patent CL2013003630, protecting methods for treating and preventing Hepatitis B using tenofovir disoproxil fumarate (TDF), has several implications for R&D and investment decisions in the pharmaceutical sector.
For Research and Development (R&D):
- Focus on Next-Generation Therapies: The existence of this patent and its likely long market exclusivity period for TDF incentivized R&D efforts towards next-generation Hepatitis B therapies. This includes exploring compounds with improved efficacy, better safety profiles, higher barriers to resistance, or alternative mechanisms of action.
- Development of Resistance-Breaking Strategies: As TDF is a cornerstone therapy, R&D may focus on understanding and overcoming potential viral resistance mechanisms to TDF. This could involve developing new combination therapies or identifying agents that are effective against TDF-resistant strains.
- Advancement of Combination Therapies: The patent's inclusion of combination therapies suggests that developing novel, synergistic combinations with TDF or its successors remains a valid R&D avenue. This could involve pairing TDF with agents targeting different viral pathways or host factors.
- Exploration of Different Tenofovir Prodrugs or Analogs: While TDF is specifically claimed, ongoing R&D might explore other tenofovir prodrugs or analogs that offer distinct pharmacokinetic or pharmacodynamic properties, potentially leading to new patentable inventions.
- Development of Alternative Treatment Regimens: R&D may also focus on optimizing treatment durations, personalized dosing strategies based on patient characteristics, or novel delivery methods that circumvent the need for daily oral administration.
For Investment:
- Opportunity in Generic Entry (Post-Patent Expiry): As the patent protection for CL2013003630 and related compound patents for TDF nears or reaches expiry, this creates significant investment opportunities for generic pharmaceutical companies. These companies can invest in developing bioequivalent generic versions of TDF-based treatments for the Chilean market, aiming to capture a share of the demand at a lower price point.
- Investment in Novel HBV Therapeutics: Investors can allocate capital to companies developing innovative Hepatitis B therapies that address unmet needs, such as treatments for patients who are refractory to existing therapies, those with advanced liver disease, or those with complex resistance profiles. This includes novel small molecules, long-acting injectables, or even therapeutic vaccines.
- Strategic Partnerships and Acquisitions: Pharmaceutical companies with established Hepatitis B portfolios might seek to invest in or acquire smaller biotechs that possess promising late-stage or early-stage HBV pipeline assets. This can accelerate R&D and expand market reach.
- High-Risk, High-Reward Venture Capital: Venture capital firms can fund early-stage biotech startups engaged in cutting-edge HBV research, accepting higher risk for the potential of substantial returns if a breakthrough therapy is developed and successfully commercialized.
- Assessment of Patent Strength and Expiry: Investors need to meticulously assess the strength and remaining life of CL2013003630 and any other relevant patents. This includes understanding the scope of the claims, potential for invalidation, and any granted extensions or supplementary protection certificates.
The existence of patent CL2013003630, during its active term, directs innovation towards new therapeutic solutions while signaling future opportunities for generic competition and investment in novel agents.
What are the Challenges and Opportunities for Generic Manufacturers Regarding CL2013003630?
For generic manufacturers targeting the Hepatitis B market in Chile, patent CL2013003630 presents both significant challenges and potential opportunities.
Challenges:
- Patent Exclusivity and Market Entry Barriers: During the effective life of CL2013003630, generic manufacturers are prohibited from making, using, selling, or importing TDF for the patented method of treating Hepatitis B in Chile. This patent acts as a primary barrier to market entry for generic TDF.
- Freedom-to-Operate (FTO) Analysis Complexity: A thorough FTO analysis is crucial and complex. Generic manufacturers must not only consider CL2013003630 but also any other potentially relevant patents covering TDF, its formulations, manufacturing processes, or other methods of use in Chile. Overlooking a single patent can lead to costly litigation and market exclusion.
- Potential for Litigation: Even if a generic manufacturer believes they are not infringing, the patent holder (Gilead Sciences) may initiate patent infringement litigation. This can be a lengthy, expensive, and uncertain process.
- Regulatory Hurdles for Generics: While patents are the primary R&D barrier, generic approval itself requires demonstrating bioequivalence to the reference product (Viread). Meeting these regulatory standards in Chile is a procedural challenge.
- Market Dynamics with Authorized Generics: If Gilead has launched or plans to launch an authorized generic around the time of patent expiry, generic manufacturers face competition from a product that may have established market share and a favorable supply chain.
Opportunities:
- Patent Expiry and Market Opportunity: The most significant opportunity arises upon the expiry of CL2013003630 and any other relevant compound or formulation patents. This opens the door for generic entry, allowing manufacturers to offer more affordable versions of TDF-based treatments.
- Development of Non-Infringing Formulations or Processes: Generic companies may explore developing alternative formulations of TDF or novel manufacturing processes that are not covered by existing patents. This requires significant R&D investment but can provide a pathway to market even if core compound patents are still in force for limited periods or specific uses.
- Challenging Patent Validity: If generic manufacturers believe CL2013003630 or related patents are invalid (e.g., due to lack of novelty, obviousness, or insufficient disclosure), they can initiate legal proceedings to have the patent revoked. Successful challenges can clear the path for generic entry.
- Market Demand for Affordable Treatments: Hepatitis B is a global health concern, and there is a significant demand for accessible and affordable treatments. Once barriers are removed, generic TDF can capture a substantial market share, particularly in regions where cost is a major factor.
- Development of Combination Generics: If patents on second antiviral agents (e.g., lamivudine, entecavir) are also expiring or have expired, opportunities exist to develop fixed-dose combination generic products that incorporate TDF with other generics, potentially simplifying treatment regimens for patients.
Successfully navigating the patent landscape, particularly understanding the exact expiry and scope of CL2013003630, is critical for generic manufacturers to strategize their entry into the Chilean Hepatitis B market.
Key Takeaways
- Patent CL2013003630 protects methods for treating and preventing Hepatitis B infection using tenofovir disoproxil fumarate (TDF) and its pharmaceutically acceptable salts, including combination therapies with specified antiviral agents.
- The patent's scope includes specific claims for treating chronic Hepatitis B in human subjects and for pharmaceutical compositions containing TDF.
- The patent landscape for Hepatitis B treatments in Chile is dynamic, featuring innovator patents, generic competition, and other antiviral agents, requiring thorough freedom-to-operate analyses.
- For R&D, the patent incentivizes the development of next-generation therapies, resistance-breaking strategies, and novel combination treatments, while for investment, it signals opportunities in generic entry post-expiry and in novel HBV therapeutics.
- Generic manufacturers face challenges from patent exclusivity and litigation but can find opportunities upon patent expiry, through non-infringing development, patent validity challenges, and meeting market demand for affordable treatments.
Frequently Asked Questions
-
What is the primary active pharmaceutical ingredient protected by patent CL2013003630 for Hepatitis B treatment?
Tenofovir disoproxil fumarate (TDF) is the primary active pharmaceutical ingredient.
-
Does CL2013003630 cover the synthesis of TDF, or its therapeutic use?
The patent claims are directed to the method of treating or preventing Hepatitis B infection and to pharmaceutical compositions containing TDF, not the method of synthesizing TDF itself.
-
Can other antiviral agents be used in combination with TDF under CL2013003630?
The patent specifically claims combination therapy with a second antiviral agent selected from lamivudine, adefovir dipivoxil, entecavir, and telbivudine.
-
What is the expected lifespan of patent protection for TDF in Chile based on this patent?
The lifespan of protection depends on the granted term of the patent, which began with its filing date and may be subject to extensions or early expiry based on various legal and regulatory factors. A specific expiry date would need to be determined by consulting official patent registers.
-
If CL2013003630 is expired, does that mean TDF-based Hepatitis B treatments are free to be marketed in Chile?
Patent expiry removes the protection offered by CL2013003630. However, other patents related to TDF (e.g., new formulations, manufacturing processes, or specific combination therapies) may still be in force, and regulatory approvals are always required.
Citations
[1] Gilead Sciences, Inc. (2013). Method for treating and preventing hepatitis B infection. Chilean Patent CL2013003630.
